Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cathryn Luria

Allergy & Immunology West Bloomfield, MI Medical Doctor

NPI 1790076057 CMS profile 4110586

5775 W Maple Rd, West Bloomfield, MI 48322

Open in the dashboard

General payments

$5,268

263 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cathryn Luria of West Bloomfield, MI is reported in the CMS Open Payments database as having received $5,268 across 263 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $915 41
2024 General $1,201 62
2023 General $1,173 63
2022 General $582 27
2021 General $569 31
2020 General $373 20
2019 General $456 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cathryn Luria
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Cathryn Luria were reported at $915. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Cathryn Luria Allergy & Immunology median Middle half National median
2019 $456 $594 $163–$1,512 $163
2020 $373 $426 $106–$1,233 $114
2021 $569 $638 $157–$1,708 $132
2022 $582 $790 $205–$1,961 $149
2023 $1,173 $852 $220–$2,147 $160
2024 $1,201 $865 $203–$2,267 $164
2025 $915 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $763 37 payments
  2. AstraZeneca Pharmaceuticals LP $687 40 payments
  3. GlaxoSmithKline, LLC. $539 34 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $398 12 payments
  5. Pfizer Inc. $337 17 payments
  6. CSL Behring $323 14 payments
  7. Novartis Pharmaceuticals Corporation $274 21 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $267 14 payments
  9. Genentech USA, Inc. $237 6 payments
  10. Regeneron Healthcare Solutions, Inc. $207 9 payments
  11. Other $1,237 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,193 262 payments
  2. Education $75 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $1,474 65 payments
  2. SPIRIVA RESPIMAT $341 18 payments
  3. NUCALA $259 15 payments
  4. FASENRA $222 12 payments
  5. CUVITRU $209 4 payments
  6. TRELEGY ELLIPTA $198 14 payments
  7. Haegarda $183 7 payments
  8. TEZSPIRE $181 9 payments
  9. XOLAIR $181 16 payments
  10. DUPIXENT Inflammation And Immunology $150 7 payments
  11. Other $3,083 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,151

Median for Allergy/ Immunology: 449

Drug cost

$650,873

Median for Allergy/ Immunology: $169,700

Branded share of claims

46.7%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Takhzyro Lanadelumab-Flyo Brand 13 $333,298
Dupixent Syringe Dupilumab Brand 17 $62,409
Cuvitru Immun Glob G(Igg)/Gly/Iga Ov50 Brand 18 $48,742
Spiriva Respimat Tiotropium Bromide Brand 53 $48,011
Breo Ellipta Fluticasone/Vilanterol Brand 63 $42,657
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 39 $36,260
Symbicort Budesonide/Formoterol Fumarate Brand 62 $19,883
Advair Hfa Fluticasone Propion/Salmeterol Brand 28 $15,565
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 38 $11,579
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 43 $8,812

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$119,412

Of which drugs: $75,407

Medicare patients

173

Average age 74

Services billed

4,760

107 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 51%
Ischemic heart disease 25%
Osteoporosis 24%
Diabetes 22%
Chronic kidney disease 21%
Depression 18%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 18 18 $1,323

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $203
  • Regeneron Healthcare Solutions, Inc. $53
$256 17 —
NUCALA
  • GlaxoSmithKline, LLC. $184
$184 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $60
  • Genentech USA, Inc. $19
$79 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $65
$65 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $64
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record